PMC:7074432 / 93-889
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
20 | 27-40 | Species | denotes | coronaviruses | Tax:11118 |
21 | 42-46 | Species | denotes | CoVs | Tax:11118 |
22 | 127-172 | Species | denotes | severe acute respiratory syndrome coronavirus | Tax:694009 |
23 | 174-182 | Species | denotes | SARS-CoV | Tax:694009 |
24 | 231-286 | Species | denotes | Middle East respiratory syndrome coronavirus (MERS-CoV) | Tax:1335626 |
25 | 353-364 | Species | denotes | coronavirus | Tax:11118 |
26 | 369-391 | Species | denotes | 2019-novel coronavirus | Tax:2697049 |
27 | 393-402 | Species | denotes | 2019-nCoV | Tax:2697049 |
28 | 519-528 | Species | denotes | 2019-nCoV | Tax:2697049 |
29 | 553-561 | Species | denotes | MERS-CoV | Tax:1335626 |
30 | 654-657 | Species | denotes | CoV | Tax:11118 |
31 | 718-721 | Species | denotes | CoV | Tax:11118 |
32 | 726-734 | Species | denotes | MERS-CoV | Tax:1335626 |
33 | 783-792 | Species | denotes | 2019-nCoV | Tax:2697049 |
34 | 79-111 | Disease | denotes | respiratory distress[1] syndrome | MESH:D012128 |
35 | 407-426 | Disease | denotes | coronavirus disease | MESH:D018352 |
36 | 428-436 | Disease | denotes | COVID-19 | MESH:C000657245 |
37 | 641-650 | Disease | denotes | infection | MESH:D007239 |
LitCovid-PMC-OGER-BB
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T41 | 27-40 | NCBITaxon:11118 | denotes | coronaviruses |
T40 | 79-90 | UBERON:0001004 | denotes | respiratory |
T39 | 127-139 | SP_10 | denotes | severe acute |
T38 | 140-151 | SP_10;UBERON:0001004 | denotes | respiratory |
T37 | 152-172 | SP_10 | denotes | syndrome coronavirus |
T36 | 174-182 | SP_10 | denotes | SARS-CoV |
T35 | 231-242 | SP_9 | denotes | Middle East |
T34 | 243-254 | SP_9;UBERON:0001004 | denotes | respiratory |
T33 | 255-275 | SP_9 | denotes | syndrome coronavirus |
T32 | 277-285 | SP_9 | denotes | MERS-CoV |
T31 | 353-364 | NCBITaxon:11118 | denotes | coronavirus |
T30 | 380-391 | NCBITaxon:11118 | denotes | coronavirus |
T29 | 393-402 | SP_7 | denotes | 2019-nCoV |
T28 | 407-418 | NCBITaxon:11118 | denotes | coronavirus |
T27 | 428-436 | SP_7 | denotes | COVID-19 |
T26 | 519-528 | SP_7 | denotes | 2019-nCoV |
T25 | 538-542 | SP_10 | denotes | SARS |
T24 | 553-561 | SP_9 | denotes | MERS-CoV |
T23 | 726-734 | SP_9 | denotes | MERS-CoV |
T22 | 741-747 | CHEBI:52217;CHEBI:52217 | denotes | agents |
T21 | 783-792 | SP_7 | denotes | 2019-nCoV |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T1 | 127-160 | Disease | denotes | severe acute respiratory syndrome | http://purl.obolibrary.org/obo/MONDO_0005091 |
T2 | 174-182 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T3 | 428-436 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T4 | 538-542 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
T5 | 641-650 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 548-550 | http://purl.obolibrary.org/obo/CLO_0001000 | denotes | 35 |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T1 | 598-607 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T3 | 0-658 | Sentence | denotes | In the 21st century, three coronaviruses (CoVs) caused three major epidemic of respiratory distress[1] syndrome, which include severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003 with epicenter in Guangdong, China,[2] Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012 in Saudi Arabia,[3] and the third epidemic of respiratory coronavirus the 2019-novel coronavirus (2019-nCoV) or coronavirus disease (COVID-19) mainly centered in Wuhan province, China.[4] The case fatalities vary from 2.5% (2019-nCoV),[5]10% (SARS), to 35% (MERS-CoV).[6] Till now, there is no approved antiviral or vaccine for the management of infection by CoV. |
T4 | 659-796 | Sentence | denotes | However, from earlier experience of the management of SERS-CoV and MERS-CoV, many agents are being used in the treatment of 2019-nCoV.[7] |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T1 | 79-99 | Phenotype | denotes | respiratory distress | http://purl.obolibrary.org/obo/HP_0002098 |